Understand the dermatology partnering landscape using intelligence from 506 real-world collaboration and licensing deals.
Dermatology Collaboration and Licensing Deals 2016-2026 provides comprehensive intelligence on 506 partnering deals involving dermatology assets, technologies and development programs.
Dermatology partnering encompasses a diverse range of therapeutic indications, technologies and development strategies, from innovative therapeutics and biologics through to broader approaches addressing inflammatory, immune-mediated and other dermatological conditions.
The report brings this activity together in one resource, enabling users to understand who is partnering, which dermatology opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across indications, technologies and stages of development.
Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.
It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in dermatology partnering.
This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
The report analyzes deals by dermatology therapeutic indication, allowing users to move beyond broad market-level benchmarks and focus on transactions most relevant to a particular program or strategic interest.
Combined with analysis by technology and development stage, this enables users to identify more meaningful comparable transactions and prospective partners.
Identify comparable dermatology transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking dermatology opportunities across particular indications, technologies and development stages.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable dermatology assets, technologies and development programs.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building dermatology portfolios through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
The briefing applies the underlying dermatology deal intelligence to the customer's own asset, technology, indication or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Dermatology Collaboration and Licensing Deals 2016-2026 provides comprehensive intelligence on 506 partnering deals involving dermatology assets, technologies and development programs.
Dermatology partnering encompasses a diverse range of therapeutic indications, technologies and development strategies, from innovative therapeutics and biologics through to broader approaches addressing inflammatory, immune-mediated and other dermatological conditions.
The report brings this activity together in one resource, enabling users to understand who is partnering, which dermatology opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across indications, technologies and stages of development.
Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.
It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in dermatology partnering.
Understand the dermatology partnering landscape
The report analyzes dermatology dealmaking from 2016 to 2026, including:
- Trends in dermatology partnering by year
- Deal activity by deal type
- Industry sector
- Stage of development at the time of partnering
- Technology type
- Dermatology therapeutic indication
- Most active dermatology dealmakers
- Leading deals by disclosed value
- How dermatology partnering activity is evolving
Benchmark dermatology deal financials
Financial terms can vary considerably according to the asset, development stage, technology, rights granted and overall transaction structure.The report provides dedicated analysis of disclosed financial terms, including:
- Headline deal values
- Upfront payments
- Milestone payments
- Royalty rates
This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
Identify leading dermatology dealmakers and prospective partners
The report identifies the most active companies in dermatology partnering and provides transaction histories that enable users to investigate their previous activity.This can help users identify:
- Companies actively seeking dermatology opportunities
- Prospective licensing and collaboration partners
- Organizations repeatedly partnering in particular dermatology indications
- Companies active at relevant stages of development
- Dealmakers demonstrating interest in specific technologies or approaches
- Competitors pursuing similar external innovation strategies
Compare partnering activity across dermatology indications
Dermatology encompasses multiple distinct therapeutic indications with different clinical, competitive and commercial dynamics.The report analyzes deals by dermatology therapeutic indication, allowing users to move beyond broad market-level benchmarks and focus on transactions most relevant to a particular program or strategic interest.
Combined with analysis by technology and development stage, this enables users to identify more meaningful comparable transactions and prospective partners.
Understand how dermatology agreements are structured
The report includes collaboration, licensing, development, research and other partnering transactions.Depending on the transaction and available disclosure, users can investigate areas including:
- Rights granted and retained
- Research and development responsibilities
- Licensing rights
- Exclusivity
- Geographic rights
- Intellectual property
- Development and regulatory obligations
- Manufacturing and supply responsibilities
- Commercialization rights
- Financial consideration
- Milestones and royalties
- Governance
- Term and termination provisions
Learn from real-world contract documents
Where publicly available, the report provides access to underlying contract documents for selected dermatology transactions.These agreements can provide substantially more detail than headline announcements alone, enabling users to examine how companies have documented areas such as:
- Scope of rights
- Development obligations
- Intellectual property
- Exclusivity
- Financial terms
- Milestone triggers
- Royalty provisions
- Commercialization rights
- Termination and other negotiated provisions
Comprehensive dermatology deal directory
The report includes a comprehensive directory of 506 dermatology collaboration and licensing deals, providing a detailed resource for identifying relevant precedent transactions.Deals can be reviewed by:
- Company
- Technology type
- Therapeutic indication
- Contract availability
Who should use this report?
Business Development and Licensing teamsIdentify comparable dermatology transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking dermatology opportunities across particular indications, technologies and development stages.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable dermatology assets, technologies and development programs.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building dermatology portfolios through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
Turn market-wide dermatology intelligence into company-specific insight
For qualifying customers, the analyst can also provide a Customized Executive Partnering Briefing alongside the report.The briefing applies the underlying dermatology deal intelligence to the customer's own asset, technology, indication or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Table of Contents
Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in dermatology dealmaking
Chapter 3 - Financial deal terms for dermatology partnering
Chapter 4 - Leading dermatology deals and dealmakers
Chapter 5 - Dermatology contract document directory
Chapter 6 - Dermatology dealmaking by therapeutic target
Deal directory
Table of figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3Derm Systems
- 3M
- 23andMe
- Abbvie
- Abex Pharmaceutica
- Ablexis
- AbSci
- Accro Bioscience
- Aclaris Therapeutics
- Adalvo
- Adaptive Phage Therapeutics
- Adhesys Medical
- Advanced Human Imaging
- Advanced Medical Solutions
- Advanz Pharma
- Advonex
- AFT Pharmaceuticals
- AiCuris
- Akaal Pharma
- Aldena Therapeutics
- Alibaba Health
- AlivaMab Discovery Services
- Allergan
- Allergan Aesthetics
- Almirall
- Alumis
- Alvotech
- Amend Surgical
- American Skin Association
- Amgen
- Amicus Therapeutics
- Amor (Suzhou) Medical Sci-Tech
- Amyris
- Amytrx Therapeutics
- ANANDA Scientific
- AnaptysBio
- AnGes MG
- Anhalt University of Applied Sciences
- Animal Allergy Clinical Laboratories
- Antibe Therapeutics
- AOBiome Therapeutics
- Aphex BioCleanse Systems
- Applied Biology
- APR Applied Pharma Research
- Aquavit Pharmaceuticals
- Arch Biopartners
- Arctic Therapeutics
- Arcutis Biotherapeutics
- argenx
- Armis Biopharma
- Arrevus
- Arrien Pharmaceuticals
- Artelo Biosciences
- Aslan Pharma
- Aspire Pharma
- AstraZeneca
- Astria Therapeutics
- Athenex
- Aucta Pharmaceuticals
- Aurealis Therapeutics
- Auson Pharmaceuticals
- Avaria Health & Beauty
- Avicanna
- AVIR Pharma
- Avita Medical MENA
- Avita Therapeutics
- Azitra
- Back-A-Line
- BASF
- Basilea Pharmaceutica
- Bausch & Lomb
- Bayer
- Beckman Research Institute of City of Hope
- Beiersdorf
- Belle.ai
- Ben-Gurion University
- BGN Technologies
- Bill and Melinda Gates Foundation
- BinnoPharm
- Bio-Gate
- Bio-Thera Solutions
- Biocogent
- Biocon
- BioCryst Pharmaceuticals
- BioDerm
- Biofrontera Pharma
- Biogen
- Biohaven Pharmaceuticals
- BioLab Sciences
- Biolojic Design
- Biomedical Advanced Research and Development Authority
- BioMed X Innovation Center
- Biomillenia
- BiomX
- BiondVax
- BioNexus Gene Lab
- Bioniz Therapeutics
- BioPep
- Biophage Pharma
- BiopharmX
- Bioqube Ventures
- BiosanaPharma
- Biosion
- Biosolution
- BioStem Technologies
- BirchBioMed
- Bodor Laboratories
- Boehringer Ingelheim
- Boragen
- Bora Pharmaceuticals
- Boston Pharmaceuticals
- Botanix Pharmaceuticals
- BoyaLife
- Brickell Biotech
- Brigham and Women's Hospital
- Bright Future Pharmaceutical Lab
- Bristol-Myers Squibb
- Brown University
- Cabaletta Bio
- Cadila Pharmaceuticals
- Camargo Pharmaceutical Services
- Can-Fite BioPharma
- Candela
- CannaSkin
- Cannassure Therapeutics
- CanniMed Therapeutics
- Canopy Growth
- Cap Alter Pharma
- Capital Laser and Skin Care
- Cara Therapeutics
- CARB-X
- Cardiome Pharma
- Carestream Health
- Cassiopea
- Castle Biosciences
- Celgene
- Cellares
- CellMark Medical
- Cell Mogrify
- Celularity
- Certara
- Ceva Sante Animale
- Charles River Laboratories
- Chelexa Biosciences
- Chemstar
- Children's Hospital Boston
- China Medical System
- Chongqing Jingdong Pharmaceutical
- Chugai Pharmaceutical
- Cipher Pharmaceuticals
- Cipla
- City of Hope
- CIVCO Radiotherapy
- CMS Aesthetics
- CMS Medical
- Codex Beauty
- Collplant
- Columbia University Medical Center
- ConvaTec
- Cook Biotech
- Cosmofix
- Cosmo Pharmaceuticals
- Covalon Technologies
- CR Double-Crane
- Crescita Therapeutics
- Cronos Group
- Crown Laboratories
- Cumberland Pharmaceuticals
- CURE Pharmaceutical
- Cutanea Life Sciences
- Cutia Therapeutics
- Cynata Therapeutics
- Cytori Therapeutics
- CytoSorbents
- Dalhousie University
- DASH Analytics
- Dechra Pharmaceuticals
- Defense Health Agency (US)
- Defense Threat Reduction Agency
- Denali Therapeutics
- Department of Defense
- Department of Veterans Affairs
- Dermala
- DermapenWorld
- Dermavant Sciences
- Dermelix Biotherapeutics
- Dermira
- DermTech
- Devonian Health Group
- DKSH
- Dong-A ST
- Dow Pharmaceutical Sciences
- Dr. Denese SkinScience
- Dr. Reddy's Laboratories
- Dr. U Devices
- Draper Laboratories
- Dr Bragi Company
- Dr Kerklaan Therapeutics
- DS Biopharma
- Dyamed Biotech
- Dynasil
- EB Research Foundation
- EB Research Partnership
- Edesa Biotech
- Egis
- Eirion Therapeutics
- Eisai
- eKare
- Elektrofi
- Elevai Labs
- Eligo Bioscience
- Eli Lilly
- Eloxx Pharmaceuticals
- Emmaus Life Sciences
- Empa
- Emphysys
- Encore Dermatology
- Endo International
- Enteris Biopharma
- Enzymatica
- Epicore Biosystems
- EPI Health
- epitoMAP
- Equillium
- Er-Kim
- EspeRare Foundation
- eTheRNA immunotherapies
- Etienna Bio
- Eton Pharmaceuticals
- Eurofins Scientific
- European Wellness Biomedical Group
- EVA Pharma
- Eve & Co
- Evolve BioSystems
- Evommune
- Evotec
- Ewopharma
- ExCEEd Orphan
- Excelra
- Exicure
- Fagron
- Felix Biotechnology
- Fesarius Therapeutics
- FibroBiologics
- Fission Labs LATAM
- Foamix Pharmaceuticals
- Fosun Pharmaceutical
- Fosun Wanbang
- Fresh Tracks Therapeutics
- Fujifilm Kyowa Kirin Biologics
- Fuji Pharma
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Galapagos
- Galderma
- Galenica
- Geisel School of Medicine at Dartmouth
- Gene Biotherapeutics
- Genentech
- George Washington University
- Gilead Sciences
- Ginkgo BioWorks
- Givaudan
- GL Brands
- Glenmark Pharmaceuticals
- GPC Systems
- Grunenthal
- GSK
- Guangzhou Xiangxue Pharmaceutical
- Hairmore Group
- Halozyme Therapeutics
- Hangzhou Zhongmei Huadong Pharmaceutical
- Happify Health
- Harvard Medical School
- Hawkeye Therapeutics
- Healiant
- Helsinn Healthcare
- Heumann Pharma Generics
- Hill Dermaceuticals
- Histogen
- HitGen
- Hope Medicine
- Hoth Therapeutics
- Houston Methodist Research Institute
- HTDK Group
- Huapont Pharma
- Hume Supernatural
- Huons
- Hyloris Pharmaceuticals
- Hyphens
- Icahn School of Medicine at Mount Sinai
- Ice + Jam
- Ichnos Sciences
- IDEAYA Biosciences
- Imbed Bio
- IME Medical Electrospinning
- IMIDomics
- Immunomic Therapeutics
- Immuthera
- Incannex Healthcare
- Incyte
- Induce Biologics
- InfectoPharm
- Infinimmune
- Innate Biologics
- Innosuisse
- Innovate UK
- Innovative Cellular Therapeutics
- Innovent Biologics
- Innovize
- Inova Diagnostics
- Intas Pharmaceuticals
- Integra LifeSciences
- International Hyperhidrosis Society
- Intralytix
- Ionis Pharmaceuticals
- IQVIA
- Isoprene Pharmaceuticals
- Jackson Laboratory
- James Cook University
- Janssen Biotech
- Janssen Pharmaceuticals
- Janssen Research & Development
- Janssen Therapeutics
- Japan Tobacco
- JCR Pharmaceuticals
- Jiangsu Hengrui Medicine
- Jiangsu QYuns Therapeutics
- Joerns Healthcare
- Johns Hopkins University
- Johnson & Johnson
- Johnson & Johnson Consumer Companies
- Johnson & Johnson Innovation
- Journey Medical
- Junshi Biosciences
- Juntendo University
- Jupiter Wellness
- Juyou Biotechnology
- JW Pharmaceutical
- Kaken Pharmaceutical
- Kaleido Biosciences
- Kane Biotech
- Kashiv BioSciences
- KBI BioPharma
- Keck School of Medicine of USC
- Kent Imaging
- Keraderm
- Kerecis
- King's College Hospital
- Kiniksa Pharmaceuticals
- KiOmed Pharma
- KNOW Bio
- Komodo Health
- Kubota Vision
- Kuria Therapeutics
- Kyocera
- Kyowa Hakko Kirin
- L'Oreal
- Lannett
- Laser Lab Corp
- Leman SKL SA
- LEO Pharma
- LGC
- LifeMax Laboratories
- Ligand Pharmaceuticals
- Lighthouse Strategies
- Lipidor
- LipoTrue
- Loreal
- Louis Widmer
- Lubrizol
- Lupin
- Lysando
- Mabwell Bioscience
- MagnaPharm Group
- MainPointe
- Mallinckrodt Pharmaceuticals
- Mamba Instruments
- Maruho
- Massachusetts General Hospital
- MatriSys Bioscience
- Max-Planck
- Mayne Pharma
- Mayo Clinic
- MC2 Therapeutics
- McMaster University
- Meabco
- Medimetriks
- MediPharm Labs
- MediWound
- Medline
- MedPharm
- MedShape
- Medshift
- Meiji Seika
- MEME
- Menlo Therapeutics
- Merakris Therapeutics
- Merck and Co
- Merck KGaA
- Merz
- Mesoblast
- Metrion Biosciences
- Michal Morrison
- Michelson Diagnostic
- Micreos
- Microbio Shanghai
- MiMedx
- MiNDERA
- miraDry
- Miravo Healthcare
- Mitsubishi Tanabe Pharma
- MLM Biologics
- Moberg Pharma
- MolecuLight
- Molnlycke Health Care
- Momenta Pharmaceuticals
- Monash University
- MoonLake Immunotherapeutics
- MorphoSys
- Moss Genomics
- MT.DERM
- MTF Biologics
- Mundipharma
- MyBiotics Pharma
- Mylan Pharmaceuticals
- Nabriva Therapeutics
- NanoPass Technologies
- NanoVibronix
- National Eczema Association
- National Institute of Allergy and Infectious Diseases
- National Institute of Arthritis and Musculoskeletal Diseases
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institutes of Health
- National Psoriasis Foundation
- National Research Council Canada
- National Research Council of Canada
- National Science Foundation
- Nationwide Laboratory Services
- Nektar Therapeutics
- New York University School of Medicine
- NEXGEL
- Nielsen BioSciences
- Nipro Corporation
- Nogra Pharma
- Nordic Pharma Group
- North Carolina State University
- Northwestern University
- NovaBay Pharmaceuticals
- Novan
- Novan Therapeutics
- Novartis
- Novelty Nobility
- Novo Nordisk
- Now Biopharma
- Nuevolution
- Nuo Therapeutics
- NurExone Biologic
- Nuvothera
- Oakrum Pharma
- Oklahoma Medical Research Foundation
- Olaregen Therapeutix
- OliX Pharmaceuticals
- Oncodesign
- Oneness Biotech
- OptiBiotix
- Or-Genix Therapeutics
- Organogenesis
- Organ Technologies
- ORIG3N
- Orphan Europe
- Orpharm
- Oruka Therapeutics
- Otsuka
- Ovation Science
- OWC Pharmaceutical Research
- Paladin Labs
- Palisade Bio
- Palvella Therapeutics
- Paradigm Therapeutics
- Paratek Pharmaceuticals
- Patagonia Pharmaceuticals
- PathogenDx
- Patient-Centered Outcomes Research Institute
- PCG Clinical Services
- PCI Pharma Services
- Pediatric Dermatology Research Alliance
- Pediatrix Therapeutics
- PellePharm
- Pelle Ventures
- Pelthos Therapeutics
- Perrigo
- Pfizer
- PharmaResearch Products
- Pharming Group
- Phosphagenics
- Pierre Fabre
- Pierre Fabre Dermatologie
- Pint Pharma
- Piqur Therapeutics
- Pixie Dust Technologies
- Popit
- Portola Pharmaceuticals
- Premier Inc
- Prescient Surgical
- Pressure BioSciences
- Prime Therapeutics
- Priovant Therapeutics
- Promius Pharma
- Promore Pharma
- Proscia
- Protagen
- Protagonist Therapeutics
- Proteic Bioscience
- Proya Cosmetics
- Pura Naturals
- Purdue Pharma
- Purnovate
- Pyramid Biosciences
- Queensland University of Technology
- Quest Pharmaceutical Services
- Quoin Pharmaceuticals
- Rational Surgical Solutions
- Realm Therapeutics
- Recludix Pharma
- Regenerative Biologics
- Regenerative Medicine of Latin America
- Regenity Biosciences
- Regranion
- Relation Therapeutics
- ReLeaf Europe
- Relife
- Renovacare
- Repertoire Immune Medicines
- Replicel Life Sciences
- Repurpose.AI
- Resilia Pharmaceuticals
- Restorix Health
- Revision Skincare
- RIKEN Yokohama Institute Omics Science Center
- Rochal Industries
- Roche
- Rodan and Fields
- ROi (Resource Optimization & Innovation)
- Roivant Sciences
- Rubedo Life Sciences
- RVL Pharmaceuticals
- Samsung Bioepis
- Samumed
- Sandoz
- Sanmina
- Sanofi
- Sanpellegrino Cosmetics
- Sanuwave Health
- SastoMed
- Sato Pharmaceutical
- SciBase
- Science 37
- ScienceMachine
- Sciton
- Scohia Pharma
- Searchlight Pharma
- Second Genome
- Sensus Healthcare
- SenzaGen
- Seqirus
- Sequence Bio
- Sequential Skin
- SerenaGroup
- Shanghai Haohai Biological Technology
- Shenzhen Beimei Pharmaceuticals
- SHL Medical
- Signum Biosciences
- Simcere Pharmaceutical
- Simris Biomimetics
- Sinclair Pharmaceuticals
- Sinovant Sciences
- Sirenas
- Sirona Biochem
- Skin and Cancer Institute
- SkinBiotix
- SkinSciPac
- Skinvisible
- Smith & Nephew
- Societal CDMO
- SoftWave Tissue Regeneration Technologies
- Sofwave Medical
- Sol-Gel
- Soliton
- Sonoma Pharmaceuticals
- Sosei Heptares
- Southwest Transplant Alliance
- StemCell Systems
- Stratpharma
- Sumitomo Chemical Company
- Sun Pharmaceutical
- SutroVax
- Suzhou Connect Biopharmaceuticals
- Swiss Institute of Allergy and Asthma Research
- Taiho
- Takeda Pharmaceutical
- Tauriga Sciences
- Technion Research and Development Foundation
- TekCyte
- Telemedicine Solutions
- Teva Pharmaceutical Industries
- Teva Pharmaceuticals USA
- TheraVida
- Thomas Jefferson University
- Thought Leadership & Innovation Foundation
- Timber Pharmaceuticals
- Tissue Analytics
- Tissue Regenix
- Tohoku University
- Torii Pharmaceutical
- Triage Technologies
- Turn Therapeutics
- TWi Biotechnology
- Tyris Therapeutics
- uBiome
- UMass Chan Medical School
- UNION Therapeutics
- University Gottingen
- University of Alabama at Birmingham
- University of Barcelona
- University of California
- San Diego
- University of California
- San Diego (UCSD) School of Medicine
- University of California Los Angeles
- University of California San Francisco
- University of Cincinnati
- University of Colorado
- University of Colorado Denver
- University of Dundee
- University of Manchester
- University of Maryland Baltimore
- University of Massachusetts
- University of New Mexico
- University of North Carolina
- University of Oxford
- University of Pennsylvania
- University of Pittsburgh
- University of South Australia
- University of Virginia
- University of Washington
- University of Wisconsin
- US Army
- US Army Medical Research and Material Command
- Valeant Pharmaceuticals
- ValenzaBio
- Vanda Pharmaceuticals
- Vanderbilt University
- Vasomune Therapeutics
- Vaxcyte
- Venturis Therapeutics
- Vericel
- Verily
- Verrica Pharmaceuticals
- Veterans Medical Distributors
- ViaDerma
- Vial
- Victoria University
- Vifor Pharma
- Vipergen
- VisionQuest Biomedical
- VisualDx
- Vitro Biopharma
- Vitruvias Therapeutics
- Vizient
- Voronoi
- Wearifi
- Weill Cornell Medical College
- Windward Bio
- Winhealth Pharma Group
- Wistar Institute
- Worcester Polytechnic Institute (WPI)
- Worldwide Clinical Trials
- WuXi Biologics
- X-chem
- Xbiome
- Xcede Technologies
- Xycrobe Therapeutics
- Xylyx Bio
- Yale School of Medicine
- YOFOTO (China) Health Industry
- ZappRx
- Zenoaq
- Zentiva
- Zenyaku Kogyo
- Zhittya Genesis Medicine
- Zuellig Pharma China
- Zymeworks
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
